Download - Breast Cancer Radiotherapy
![Page 1: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/1.jpg)
What’sWhat’s NewNew ininBreastBreast CancerCancer RadiotherapyRadiotherapy??
Roger M. Macklis, M.D.Cleveland Clinic Lerner College of Medicine
Cleveland Clinic Healthcare System
![Page 2: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/2.jpg)
What’s New in What’s New in Breast Cancer Radiotherapy?Breast Cancer Radiotherapy?
Recent Meta-Analysis from“Lancet”
Partial Breast Irradiation
Intensity Modulated Radiation Therapy (IMRT)
RM 9/05
![Page 3: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/3.jpg)
BREAST CANCER COMMANDS ATTENTIONBREAST CANCER COMMANDS ATTENTION
“Few topics in medicine engender as much emotional response as the treatment of primarybreast cancer.”
- Levene, Harris, HellmanCancer (1977)
RM 9/05
![Page 4: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/4.jpg)
Early InvestigationsEarly Investigations
Charles H. Moore, 1867 (surgeon to the Middlesex Hospital, London).
“ … Cancer of the breast requires the carefulextirpation of the entire organ; that the situationin which this operation is most likely to beincomplete is at the edge of the mamma near the sternum …”
RM 9/05
![Page 5: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/5.jpg)
Early InvestigationsEarly Investigations
William Halsted, 1852-1922(surgeon to the Johns Hopkins Hospital, Baltimore).
“ Most of us have heard our teacher in surgery admitthat they never cured a case of cancer of the breast …Everyone knows how dreadful the end-results were before cleaning out the axilla became recognized as an essential part of the operation.”
RM 9/05
![Page 6: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/6.jpg)
Early InvestigationsEarly Investigations
Sir Geoffrey Keynes, 1920s(St. Bartholomew Hospital, London).
Interstitial radium implants of tumor bed andsurrounding regions of the breast. “ … treatmentof choice for very advanced breast cancer.”
RM 9/05
![Page 7: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/7.jpg)
Breast Cancer: Critical Benchmark StudiesBreast Cancer: Critical Benchmark Studies
NASBP (NEJM 2002: 347 1233-1241)20 year F/U shows lumpectomy + XRT 14% LRRlumpectomy alone 39.2% LRR
Milan (Ann Oncol 2001 12: 997-1003)Quadrantectomy + XRT 5.8% LRRQuadrantectomy alone 23.5% LRRQuadrantectomy alone 23.5% LRR
New Meta-Analysis from Lancet 12/05
RM 9/05
![Page 8: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/8.jpg)
New Meta-Analysis Data on Breast Radiotherapy
strongly suggests that in addition to improving
local control, radiotherapy ALSO improves survival
![Page 9: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/9.jpg)
MetaMeta--Analysis of Breast Cancer XRTAnalysis of Breast Cancer XRT
Title: Effects of radiotherapy and of differencesin the extent of surgery for early breast canceron local recurrence and 15-year survival: anoverview of the randomised trials
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Lancet 366:2087-2106 (2005)Published Dec. 17, 2005
![Page 10: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/10.jpg)
MetaMeta--Analysis of Breast Cancer XRTAnalysis of Breast Cancer XRT
Meta-Analysis of 78 randomized controlled trialsbeginning by 1995. These trials included approximately42,000 women and roughly ¾ were involved in XRT vsno XRT trials for either conservation therapy (intactbreast) or post-mastectomy therapy. Trials separated into groups showing > or < 10% difference in LR.
![Page 11: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/11.jpg)
Data from Lancet MetaData from Lancet Meta--Analysis Analysis (N=42,000)(N=42,000)
XRT No XRT5 year local recurrence: 7% 26%(conservation-intact breast)
Post-Mastectomy (LN+) 6% 23%
15 year breast cancer mortality 30.5% 35.9%(intact breast)
15 year breast cancer mortality 54.7% 60.1%(post-mastectomy LN+)
• Overall all-cause reduction in mortality approx 4.4%!• Similar proportional reductions in all groups• Major XRT-related toxicities included cardiac disease (RR 1.27)
lung ca (RR 1.78) and contralateral breast ca (RR 1.18)
![Page 12: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/12.jpg)
Interpretation of MetaInterpretation of Meta--Analysis Data:Analysis Data:
“Differences in local treatment that substantially affectlocal recurrence rates would, in the hypothetical absenceof any other causes of death, avoid about one breastcancer death over the next 15 years for every four localrecurrences avoided, and should reduce 15-year overallmortality.” Lancet 366:2087 (2005)
Will new treatment approaches further improve this Will new treatment approaches further improve this data set?data set?
![Page 13: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/13.jpg)
CRITICAL QUESTIONS ON CRITICAL QUESTIONS ON PARTIAL BREAST IRRADIATIONPARTIAL BREAST IRRADIATION
Can less than the entire breast be treated?If so, for which types of cases? Which portion of the breast? How big a margin? External beam vs. brachytherapy? What about overall cosmesis? What about adjuvant systemic therapy?
RM 9/05
![Page 14: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/14.jpg)
General Approaches to General Approaches to Partial Breast RadiotherapyPartial Breast Radiotherapy
Interstitial implant brachytherapyIntra-Operative RadiotherapyExternal beam radiotherapyMammoSite brachytherapy
RM 9/05
![Page 15: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/15.jpg)
Interstitial Implant Breast BrachytherapyInterstitial Implant Breast Brachytherapy
1. Ochsner Clinic Team (King et al, 2000)
50 pts: Tis, T1, T2 up to 4 cmӨ margins; ≤ 3 ⊕ LNTarget Tissue: tumor surgical bed plus 2-3 cm marginEither LDR or HDR techniqueDose: 45 Gy LDR or 32 Gy (4 day BID) HDRWith median f/u 75 months, 1 breast and 3 LN recurrences seenCosmetic Outcomes: 75% good to excellent(less than 85-90% for external beam)
RM 9/05
![Page 16: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/16.jpg)
Interstitial Implant Breast BrachytherapyInterstitial Implant Breast Brachytherapy
2. William Beaumont Team (Vicini et al, 2003)
198 pts: Tis, T1, T2 ≤ 3 cmӨ margins; age >40; Ө LNTarget similar to Ochsner groupDose: LDR 50 Gy or LDR 3.4 Gy BID x 5 daysCosmetic Outcome “good to excellent” 99%!!Local recurrence rate 1% at 5 yearsBasis for subsequent RTOG trial whichopened in 1997
RM 9/05
![Page 17: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/17.jpg)
IntraIntra--Operative Breast IrradiationOperative Breast Irradiation
London study using Intrabeam device (PhotoElectron, now owned by Zeiss)Spherical applicators of different sizes50 kv orthovoltage beam producing 5 Gy at 1 cm from application surfaceClinical trial by Tobias et al. now underway;each site chooses its own entrance criteria.Other intra-op programs at MSK, etc.CCF used for boost only. Veronesi (Milan)just published results of 590 pts treated withintra-op electron beam; 21 Gy single fraction.3% breast fibrosis, 6/590 ipsilat. recurrenceafter 2-year median f/u. [Ann. Surg 242:101(2005)]
RM 9/05
![Page 18: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/18.jpg)
External Beam Partial Breast IrradiationExternal Beam Partial Breast Irradiation
William Beaumont group – developed as non-invasive analog to implant studies3D conformal XRTTarget Tissue: tumor bed plus 2-3 cm (breathing margin)34-38.5 Gy BID over 5-7 daysRTOG 95-17 phase II protocol: 38.5 Gy BID over 5-7 daysExcellent results led to current RTOG/NSABP PBI trial
RM 9/05
![Page 19: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/19.jpg)
MammoSiteMammoSite Balloon BrachytherapyBalloon Brachytherapy
Catheter resembling Foley but with 2channels: one for saline (expander) anda second for radioactive source (Ir-192)Placed directly in lumpectomy cavityeither at time of original lumpectomy orin a second procedure (single scar)Dose: 34 Gy BID in 5-7 daysWith median F/U 29 months, local failurerate 0% and cosmesis good-to-excellentin 84%.FDA clearance granted 2002Said to be the most rapidly growing breastcancer radiation procedure in the USA.
RM 9/05
![Page 20: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/20.jpg)
RM 9/05
MammoSiteMammoSite: Coming to a Clinic Near You!: Coming to a Clinic Near You!
![Page 21: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/21.jpg)
Current RTOG / NSABP TrialCurrent RTOG / NSABP Trial
Phase III randomized comparison of whole breastvs. short-course partial breast XRTStage 0, I, or II with T<3cmNo more than 3 histologically positive nodesPost-surgical CT evaluations of lumpectomy cavityDefined ratios of partial-breast to whole-breastvolumesEither interstitial catheters, Mammo Site, or 3D conformal (NOT IMRT) radiotherapyTwice daily for 10 fractions over 5-7 daysNo data available yet
RM 9/05
![Page 22: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/22.jpg)
BREAST IMRTBREAST IMRT
RM 9/05
![Page 23: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/23.jpg)
Breast IMRTBreast IMRT
Intensity Modulated Radiation Therapy (IMRT) refers to aset of related processes involving both radiation treatment planning and beam delivery. Unlike conventional radiationtreatments, which often strive to deliver uniform radiationdoses to large regions of tissue, IMRT allows small beamlets to be used to change the shape and intensity of the radiation field (sort of like a dot-matrix printer). Thisallows the radiation team to focus the field more intenselyon tumor deposits and limit the dose to nearly normaltissues.
RM 9/05
![Page 24: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/24.jpg)
RM 9/05
CCF Breast IMRT (T. CCF Breast IMRT (T. DjemilDjemil, Ph.D.), Ph.D.)
“Breast Forward IMRT Planning”Start with routine tangential fields and then adjust each segmentof the plan to minimize hot spotsNumber of segments related to hot spot location and intensity
![Page 25: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/25.jpg)
RM 9/05CCF Multislice Coplanar Breast IMRTCCF Multislice Coplanar Breast IMRTWith Concurrent Boost to Tumor BedWith Concurrent Boost to Tumor Bed
Usually 4-5 segments per field or 10 segments total
![Page 26: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/26.jpg)
BREAST IMRTBREAST IMRT
Basic Principles of Ochsner Approach
6 Field Treatment technique
3 Medial Fields + 3 Lateral Fields
Left Breast: 300, 315, 340, 110, 125, 150 Degrees
Right Breast: 200, 230, 250, 20, 45, 60 Degrees
No immobilization used
Same margins as 3D conformal technique used for IMRT
RM 9/05
![Page 27: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/27.jpg)
BREAST IMRTBREAST IMRT
Breast IMRT
6 Fld Technique
Note that veryperipheral deepportion of breast may be under-treated but amount of heart and lung irradiated is very small.
RM 9/05
![Page 28: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/28.jpg)
BREAST IMRTBREAST IMRT RM 9/05
![Page 29: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/29.jpg)
BREAST IMRTBREAST IMRT
Breast IMRT
Boost to deep lesions
RM 9/05
![Page 30: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/30.jpg)
Breast IMRT:Breast IMRT:Why do we need it?Why do we need it?
More conformal dose to breast
Lower doses to lungs and heart
Lower doses to contralateral breast
Field within a field (“concurrent boost”)
Inclusion of regional nodes
RM 9/05
![Page 31: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/31.jpg)
Breast IMRT:Breast IMRT:Why do we need it?Why do we need it?
More conformal dose to breastMore conformal dose to breastLower doses to lungs and heartLower doses to contralateral breastField within a field (“concurrent boost”)Inclusion of regional nodes
More Conformal Dose to BreastMore Conformal Dose to Breast
The natural taper of the breast produces hot spots of 3-20% unless customized wedge compensators utilized.IMRT can dramatically reduce these hot spots.
RM 9/05
![Page 32: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/32.jpg)
Breast IMRT:Breast IMRT:Why do we need it?Why do we need it?
More conformal dose to breastLower doses to lungs and heartLower doses to lungs and heartLower doses to contralateral breastField within a field (“concurrent boost”)Inclusion of regional nodes
Lower Doses to Lungs and HeartLower Doses to Lungs and Heart
Dose is ordinarily fairly low even using routine tangential fields.Typical CCF case of left sided breast cancer shows that total median dose to left lung and left ventricle will be ≤ 500 cGy.For cases of abnormal anatomy or serious pre-existing organ damage, this improvement may be significant.MSK treatment position is prone, so natural weight ofbreasts pull target away from lung and heart tissue.
RM 9/05
![Page 33: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/33.jpg)
Breast IMRT:Breast IMRT:Why do we need it?Why do we need it?
More conformal dose to breastLower doses to lungs and heartLower doses to contralateral breastLower doses to contralateral breastField within a field (“concurrent boost”)Inclusion of regional nodes
Lower Doses to Contralateral BreastLower Doses to Contralateral Breast
Dose to contralateral breast typically 2-5 Gy from a routine course of tangent field XRT.Recent data from Netherlands presented at ASCO covered 999 cases of metachronous contralateral breast ca. Use of XRT associated with 60% increase in risk for patients <40!!
RM 9/05
![Page 34: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/34.jpg)
Breast IMRT:Breast IMRT:Why do we need it?Why do we need it?
More conformal dose to breastLower doses to lungs and heartLower doses to contralateral breastField within a field (“concurrent Field within a field (“concurrent boost”)boost”)Inclusion of regional nodes
Field Within a Field (“Concurrent Boost”)Field Within a Field (“Concurrent Boost”)
Strategic use of dose inhomogeneity is one of the strong arguments for IMRT at many body sites.
RM 9/05
![Page 35: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/35.jpg)
Breast IMRT:Breast IMRT:Why do we need it?Why do we need it?
More conformal dose to breastLower doses to lungs and heartLower doses to contralateral breastField within a field (“concurrent boost”)Inclusion of regional nodesInclusion of regional nodes
Inclusion of Regional NodesInclusion of Regional Nodes
Current investigational work ongoing for inclusion of internal mammary nodes.Significant dose to adjacent areas in many cases.
RM 9/05
![Page 36: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/36.jpg)
Controversies Involving Controversies Involving Partial Breast IrradiationPartial Breast Irradiation
How much treatment margin necessary? (remember Milan quadrantectomy trial yielded 23% LRR)Which patients appropriate?(young age is powerful risk factor for local recurrence; important limitationof MammoSite device is that breast tissue must be greater than 3cm in thickness where the device is placed and there must be at least 7-to-10 mm of distance between the MammoSite balloon and skin to prevent skin injury and possible wound breakdown.)Because local recurrence has minimal impact on survival, could we define a patient group with a low enough risk that no XRT (i.e., hormonetherapy only) is necessary? (recent data for women >70 shows LRR 4%without XRT and 1% with XRT)Will the excellent 3-5 year results for each of these partial breast treatmenttechniques hold up over time?To what degree should we be driven by patient “consumerist” desires forshort-course treatment?
RM 9/05
![Page 37: Breast Cancer Radiotherapy](https://reader034.vdocuments.us/reader034/viewer/2022042508/554b5a90b4c9051b458b4d22/html5/thumbnails/37.jpg)
What’sWhat’s NewNew ininBreastBreast CancerCancer RadiotherapyRadiotherapy??
Roger M. Macklis, M.D.Cleveland Clinic Lerner College of Medicine
Cleveland Clinic Healthcare System